Erin Newburn, MS, PhD
Director, Field Applications Scientist
Monday, May 17 | 11:10am – 11:40am BST (UTC+1)
ImmunoID NeXT Platform® for comprehensive tumor immunogenomics and advanced biomarker discovery
- By combining highly sensitive, exome-scale DNA and RNA sequencing with advanced analytics, ImmunoID NeXT provides a multidimensional view of the tumor and the tumor microenvironment (TME) from a single sample preparation.
- We will feature a case study in a cohort of 51 late-stage melanoma patients demonstrating the integration of neoantigen burden, HLA LOH, and Antigen Presentation Machinery (APM) mutational data formed a composite biomarker that more accurately predicted response to checkpoint blockade than other markers.
- Additionally, we’ll highlight our NeXT Liquid Biopsy, an exome-wide liquid biopsy approach combined with ImmunoID NeXT™, to further explore critical areas of tumor biology.